Single User License
INR 128960
Site License
INR 257920
Corporate User License
INR 386880

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Chondrosarcoma-Pipeline Review, H1 2015

Chondrosarcoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6802IDB
  • |
  • Pages: 98
  • |
  • June 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Chondrosarcoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Chondrosarcoma-Pipeline Review, H1 2015', provides an overview of the Chondrosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chondrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chondrosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chondrosarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chondrosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chondrosarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Chondrosarcoma Overview 6

Therapeutics Development 7

Pipeline Products for Chondrosarcoma-Overview 7

Pipeline Products for Chondrosarcoma-Comparative Analysis 8

Chondrosarcoma-Therapeutics under Development by Companies 9

Chondrosarcoma-Therapeutics under Investigation by Universities/Institutes 10

Chondrosarcoma-Pipeline Products Glance 11

Clinical Stage Products 11

Chondrosarcoma-Products under Development by Companies 12

Chondrosarcoma-Products under Investigation by Universities/Institutes 13

Chondrosarcoma-Companies Involved in Therapeutics Development 14

Agios Pharmaceuticals, Inc. 14

Celgene Corporation 15

CytRx Corporation 16

Karyopharm Therapeutics, Inc. 17

Merck & Co., Inc. 18

Novartis AG 19

Chondrosarcoma-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

AG-120-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

aldoxorubicin hydrochloride-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CC-90007-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

pazopanib hydrochloride-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

pembrolizumab-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Peptide to Target COX-2 and MAS-GPCR for Oncology-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

selinexor-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Chondrosarcoma-Recent Pipeline Updates 56

Chondrosarcoma-Dormant Projects 93

Chondrosarcoma-Discontinued Products 94

Chondrosarcoma-Product Development Milestones 95

Featured News & Press Releases 95

May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 95

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

Number of Products under Development for Chondrosarcoma, H1 2015 7

Number of Products under Development for Chondrosarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Products under Investigation by Universities/Institutes, H1 2015 13

Chondrosarcoma-Pipeline by Agios Pharmaceuticals, Inc., H1 2015 14

Chondrosarcoma-Pipeline by Celgene Corporation, H1 2015 15

Chondrosarcoma-Pipeline by CytRx Corporation, H1 2015 16

Chondrosarcoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17

Chondrosarcoma-Pipeline by Merck & Co., Inc., H1 2015 18

Chondrosarcoma-Pipeline by Novartis AG, H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Mechanism of Action, H1 2015 24

Number of Products by Stage and Route of Administration, H1 2015 26

Number of Products by Stage and Molecule Type, H1 2015 28

Chondrosarcoma Therapeutics-Recent Pipeline Updates, H1 2015 56

Chondrosarcoma-Dormant Projects, H1 2015 93

Chondrosarcoma-Discontinued Products, H1 2015 94

List of Figures

Number of Products under Development for Chondrosarcoma, H1 2015 7

Number of Products under Development for Chondrosarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 21

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 27

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Agios Pharmaceuticals, Inc.

Celgene Corporation

CytRx Corporation

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Novartis AG

Chondrosarcoma Therapeutic Products under Development, Key Players in Chondrosarcoma Therapeutics, Chondrosarcoma Pipeline Overview, Chondrosarcoma Pipeline, Chondrosarcoma Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]